2 results match your criteria: "Cleveland Clinic Foundation Cancer Center[Affiliation]"

Ifosfamide is an alkylating agent that has demonstrated efficacy in the treatment of several malignancies. Preclinical data also support non-cross-reactivity between cyclophosphamide and ifosfamide in several cell lines. These data suggest that ifosfamide may be highly effective in the salvage setting for breast cancer patients who have received previous treatment with cyclophosphamide.

View Article and Find Full Text PDF

Ifosfamide in the treatment of soft tissue sarcomas.

Semin Oncol

June 1996

Department of Hematology/Medical Oncology, Cleveland Clinic Foundation Cancer Center, OH 44195, USA.

Ifosfamide is one of the three most active agents in the treatment of soft tissue sarcomas. Ifosfamide-induced urothelial toxicity has been adequately controlled with the use of hydration and the uroprotective agent mesna. This is a review of pilot and phase I and II studies of ifosfamide as a single agent and randomized trials of combination chemotherapy regimens incorporating ifosfamide in the treatment of soft tissue sarcomas.

View Article and Find Full Text PDF